GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches
New Data Add To Confidence
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
